Hepatocellular carcinoma (HCC) remains a lethal malignancy with a persistently poor prognosis. While our previous studies established the anti-tumor function of Deoxyribonuclease I Like Protein 3 (DNASE1L3) in HCC, the underlying mechanisms involving the immune microenvironment are less understood. Here, we demonstrate that loss of DNASE1L3 accelerated HCC progression by impairing M1-type macrophage polarization in Dnase1l3 knockout (KO) mice, co-culture models, RNA-seq, and comprehensive molecular/cellular analyses. Mechanistically, DNASE1L3 deletion suppresses tumor-associated macrophages (TAMs) polarization toward the M1 phenotype and inhibits pyroptosis by attenuating the NLRP3 inflammasome/gasdermin D (GSDMD) pathway in vitro and in vivo, thereby reducing pyroptosis in HCC cells. This regulation involves impaired nuclear translocation of NF-κB p65. Crucially, NLRP3 agonism partially reversed DNase1L3-deletion-induced suppression of the NLRP3-GSDMD axis and restored M1 polarization. Our findings reveal DNase1L3 as a pivotal regulator of TAM phenotype via the NF-κB/NLRP3-GSDMD axis and highlight its potential for immunotherapy targeting macrophage reprogramming in HCC.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: